Abstract
In China, while National Reimbursement Drug List (NRDL) inclusion is considered the best pathway to maximize originator’s market uptake, a “price for volume” strategy for considerable price cuts is common. Additionally, upon generic entry, originators may face further price cuts through volume-based procurement (VBP). The considerable price cuts and yearly rule changes have made understanding potential pricing outcomes in China a challenge. Therefore, this study aimed to determine the current important pricing checkpoints in China.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
